Phaseline

Companies › Laminar Pharmaceuticals

Laminar Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LAM561–Phase 2Primary Glioblastoma; High-grade GliomaNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04250922LAM561Phase 2Primary GlioblastomaOncologyNov 2026
NCT04299191LAM561Phase 1High-grade GliomaOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.